Darrell Borger Email and Phone Number
As a passionate advocate for transformative cancer therapies, I am committed to uncovering novel insights into targetable tumor mechanisms and predictive biomarkers that enhance therapeutic efficacy. By developing and integrating cutting-edge technologies and advanced informatics, I have defined core target signatures and drug mechanisms of action, paving the way for collaboration and synergy between discovery research, clinical trial development and research clinicians.With extensive experience in team building and leadership, translational oncology research, biomarker discovery, preclinical and clinical lab development, cutting-edge technology implementation, cancer metabolism modulation, immune oncology drug discovery, and small molecule therapies, I am dedicated to pioneering innovative cancer treatments. My goal is to significantly improve patient outcomes by developing state-of-the-art therapies and identifying those patients most likely to benefit.
Innovamark Technologies
View- Website:
- takedaoncology.com
- Employees:
- 1797
-
Managing DirectorInnovamark TechnologiesCambridge, Ma, Us
-
Director, Translational Science, Head Of Exp. & Molecular Pathology, Oncology Therapeutic Area UnitTakeda Oncology Dec 2021 - PresentCambridge, Massachusetts, United StatesFounded and directed Takeda's Experimental & Molecular Pathology Unit, integrating translational expertise, on-site laboratory capabilities, advanced tissue-based technologies, and informatics to uncover breakthrough drug targets, complex mechanisms of action, and predictive biomarkers of therapeutic response. Notable achievements include pioneering spatial multi-omics technologies, implementing custom multiplex protein/RNA panels, developing AI-based image informatics platforms at an enterprise level, and creating a comprehensive translational tumor biobank with patient tumor specimens and paired metadata. Close collaborations with Research & Development and Clinical Pathology teams are facilitating development of innovative approaches that have significantly advanced oncology drug discovery across multiple therapeutic strategies, while ensuring a seamless transition into early-phase clinical trials. -
Assoc Dir, Translational Science, Head, Integrated Translational Technol Lab, Oncology Drug Dev UnitTakeda Oncology Nov 2018 - Dec 2021Cambridge, United StatesRecruited key academic and biotechnology subject matter experts, developed a highly integrated investigative immunohistology team, improved image informatics capabilities, and overhauled preclinical laboratory practices to enhance workflow efficiency and maximize data quality. By integrating translational scientists directly into oncology drug discovery teams, we have advanced drug discovery and expanded translational capabilities across our preclinical programs using multi-target tissue-based assays. Further validation of our custom research-use-only assays into laboratory-developed tests has bridged the gap between oncology drug discovery and clinical trial development, enhancing our ability to translate research findings directly into clinical applications.
-
Scientific DirectorMassachusetts General Hospital Aug 2017 - Oct 2018Greater Boston AreaCreated and managed a preclinical lab group within the Biomarker Unit to advance precision medicine in immunotherapy. Pioneered multiplexed expression profiling and multispectral imaging to uncover immune escape mechanisms in various solid tumors. Secured a research partnership with Tesaro to identify immune checkpoint signatures in endometrial and cervical cancers, shaping future clinical trial strategies. -
Director, Biomarker Unit - Translational Research LaboratoryMassachusetts General Hospital Sep 2012 - Oct 2018Transformed a unit to implement a precision medicine approach, stratifying patients for early-phase clinical trials of small molecule inhibitors based on tumor fingerprints. Managed a central testing laboratory for six oncology trials with leading pharmaceutical companies, developing and validating genotyping assays for patient eligibility determination, including ALK/ROS1 translocations, MET gene amplification, and KIT mutations. Developed clinical exploratory assays to identify drug action and therapeutic response correlates across five early-phase trials for Constellation Pharmaceuticals and EMD Serono in various malignancies. Contributed to radiation oncology research by identifying DNA damage repair mechanisms that affect radiation therapy responses and informed co-therapy approaches. Promoted global personalized medicine by advising the Turkish Health Minister on establishing a national tumor genotyping program.
-
Co-Director, Translational Research LaboratoryMassachusetts General Hospital Feb 2007 - Aug 2012Served as an integral member of a small pathology team that developed a new generation of multiplexed clinical genotyping platforms to identify oncogenic gene mutations that could rationally inform small molecule therapy choice for patients. Developed a clinical testing lab under CLIA & New York State certification that provided one of the first examples of a hospital-implemented precision medicine approach that continues to help our clinicians direct therapy to the individual cancer patient based on an underlying tumor signature. Underwent FDA audit for approval of a CDx co-developed by the lab for directing labeled use of crizotinib.
-
Instructor In MedicineHarvard Medical School Mar 2007 - Oct 2018Greater Boston AreaIdentified novel molecular signatures in various rare malignancies, leading to the development of new phase I and II clinical trials in collaboration with MGH oncologists and leading pharmaceutical companies.• Co-identified an EGFR gene amplification signature in vulvar cancer (PMID: 18768215), prompting an MGH-sponsored phase II clinical trial of erlotinib treatment in this historically underserved patient population (PMID: 22750258).• First to report mutations in isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma (PMID: 22180306), leading to an MGH clinical trial evaluating ivosidenib (PMID: 32416072) and subsequent FDA orphan drug designation for the treatment of this rare malignancy. -
Research FellowDana-Farber Cancer Institute 2001 - 2007Discovered specific cancer survival mechanisms under low oxygen conditions and the co-opting of coactivators by a viral oncoprotein, supported through NIH funding.
Darrell Borger Education Details
-
Biomedical Science
Frequently Asked Questions about Darrell Borger
What company does Darrell Borger work for?
Darrell Borger works for Innovamark Technologies
What is Darrell Borger's role at the current company?
Darrell Borger's current role is Managing Director.
What schools did Darrell Borger attend?
Darrell Borger attended University Of South Carolina School Of Medicine.
Who are Darrell Borger's colleagues?
Darrell Borger's colleagues are Jerome Counihan, Tower Wen, Jennifer Thompson Giezek, Scott Burnette, Shonak Simlote, Chris Bos, Natalia Tkachenko.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial